WO1991006563A1 - Reduced irreversible bombesin antagonists - Google Patents
Reduced irreversible bombesin antagonists Download PDFInfo
- Publication number
- WO1991006563A1 WO1991006563A1 PCT/EP1990/001836 EP9001836W WO9106563A1 WO 1991006563 A1 WO1991006563 A1 WO 1991006563A1 EP 9001836 W EP9001836 W EP 9001836W WO 9106563 A1 WO9106563 A1 WO 9106563A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gly
- residue
- leu
- ala
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to peptide derivatives, to pharmaceutical compositions containing them, to processes for their preparation, and to their application as therapeutic agents.
- AA amino acid
- Ac acetyl
- AcOEt ethylacetate
- BBS bombesin
- Boc t-butoxycarbonyl
- BuOH n-butyl alcohol
- BOP benzotriazolyloxy-tris[dimethylamino]phosphonium hexafluorophosphate
- DMAP 4-dimethylaminopyridine
- DMF freshly distilled dimethylformamide
- DMSO dimethylsulfoxide
- Dnp 2,4-di- nitrophenyl
- EGF epidermal growth factor
- EtOH ethyl alcohol
- FAB epidermal growth factor
- EtOH
- the invention provides a peptide of the formula I:
- R represents a group of the formula
- CH 2 CBrCO- (either cis or trans isomers);
- CH 2 -CH-CH 2 -CO-; CH C-CO-; ClCH 2 CH 2 CH 2 N(NO)CO-;
- A represents a valence bond, or a Gly, Leu-Gly, Arg-Leu-Gly, or
- B represents a valence bond or a Asn, Thr or phe residue
- C represents a Gin or His residue
- X represents a Gly or ala residue
- Y represents a valence bond, or a His(R 3 ), his(R 3 ), Phe, phe, Ser, ser, Ala or ala residue;
- T represents a valence bond, or a Leu, leu, Phe or phe residue
- W represents a group of the formula OR 2 , NH 2 , NH(CH 2 ) 4 CH 3 ,
- R 1 represents a hydrogen atom, a Boc group or an acyl group having from 1 to 11 carbon atoms.
- R 2 represents a hydrogen atom, a linear or branched alyphatic chain having from 1 to 11 carbon atoms, a benzyl or a phenyl group.
- Preferred alyphatic chains which R 2 may represent include methyl, ethyl, n-propyl-, iso-propyl, n-butyl and iso-butyl groups.
- R 3 represents a hydrogen atom or a Tos, Dnp or Bzl group
- R 4 represents NH 2 , NH-NH 2 or OR 2 .
- one or more peptide bonds are replaced by reduced peptide bonds (CH 2 NH).
- Preferred acyl group which R 1 may represent are aliphatic acyl group such as acetyl, formyl, propionyl and butirryl or aromatic such as benzoyl optionally substituted by nitro, methoxy, amino group or halogen atoms.
- R represents pMel or Cab
- R 1 represents hydrogen atom, Boc or acetyl group
- A represents a valence bond
- B represents a valence bond or phe residue
- C represents a Gin residue
- X represents a His (Dnp), His or Gly residue most preferably Gly
- Y represents a valence bond
- T represents a Leu residue
- W represents a group of the formula Leu-NH 2 or Nle-NH 2
- the reduced peptide bond (CH 2 NH) is that between T and W. Salts of these peptides with pharmaceutically acceptable acids are within the scope of the invention.
- Such acid addition salts can be derived from a variety of inorganic and organic acids such as sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, nitric, sulfamic, citric, lactic, pyruvic, oxalic, maleic, succinic, tartaric, cinnamic, acetic, trifluoracetic, benzoic, salicylic, gluconic, ascorbic and related acids.
- inorganic and organic acids such as sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, nitric, sulfamic, citric, lactic, pyruvic, oxalic, maleic, succinic, tartaric, cinnamic, acetic, trifluoracetic, benzoic, salicylic, gluconic, ascorbic and related acids.
- the synthesis of the peptides of the invention may be accomplished by classical solution methods.
- the synthesis consists essentially of appropriate successive condensations of protected amino acids or peptides. The condensations are carried out so that the resulting peptides have the desired sequence of amino acid residues.
- amino acids and peptides which can be condensed according to methods known in peptide chemistry, have the amino and carboxyl groups, not involved in peptide bond formation, blocked by suitable protecting groups capable of being removed by acid or alkali treatment or by hydrogenolysis.
- the following protective groups may, for example, be employed: benzyloxycarbonyl, t-butoxycarbonyl, trityl, formyl, trifluoracetyl, o-nitrophenylsulphenyl, 4-methyloxybenzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, 3,5-dimethoxy- ⁇ - ⁇ '-dimethylbenzyloxycarbonyl or methylsulphonylethoxycarbonyl.
- the following protective groups may, for example, be employed: methyl, ethyl, t-butyl, benzyl, p-nitrobenzyl or fluorenylmethyl, amide, hydrazide, t-butoxycarbonyl hydrazide or benzyloxycarbonyl hydrazide.
- the hydroxy functions of hydroxy amino acids and the imino function of histidine may be protected by suitable protecting groups (throughout all the synthesis or only during a few steps) or may be unprotected.
- the following protective groups may, for example, be employed; t-butyl, benzyl, acetyl.
- the following groups may, for example, be used: 2,4-dinitrophenyl, tosyl, benzyl.
- De-protecting reactions are carried out according to methods known per se in peptide chemistry.
- the condensation between an amino group of one molecule and a carboxyl group of another molecule to form the peptidic linkage may be carried out through an activated acyl-derivative such as a mixed anhydride, an azide or an activated ester, or by direct condensation between a free amino group and a free carboxyl group, in the presence of a condensing agent such as dicyclohexylcarbodiimide, alone or together with a racemization preventing agent, such as N-hydroxysuccinimide or 1-hydroxybenzotriazole, or together with an activating agent such as 4-dimethylamino-pyridine.
- the condensation may be carried out in a solvent such as dimethylformamide, dimethylacetamide, pyridine, acetonitrile, tetrahydrofuran or N-methyl-2-pyrrolidone.
- the formation of a reduced peptide bond is accomplished by condensation of an N-protected amino acid aldehyde with a C-protected amino acid or peptide in the presence of a reducing agent, such as NaBH 3 CN.
- the aldehyde is usually obtained by condensing an N-protected amino acid with N,O-dimethylhydroxylamine, and reducing the resulting amide with a suitable reducing agent, such as LiAlH 4 .
- the reaction temperature may be from -30°C to room temperature.
- the reaction time is generally from 1 to 120 hours.
- the scheme of synthesis, the protecting groups and condensing agents are selected so as to avoid the risk of racemization.
- the peptides of the present invention are endowed with potent antagonism versus "in vitro” and "in vivo” effects induced by bombesin, such as contraction of smooth musculature, modification of behaviour of central origin and mitogenesis.
- Bombesin is a tetradecapeptide of formula Glp-Gln-Arg-Leu- Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH 2 , originally isolated from the skin of a frog.
- the biological activity resides in the C-terminal part of the molecule: BBS(6-14)nonapeptide is as active as the parent compound.
- the human counterpart of bombesin is a 27 amino acid peptide, known as gastrin-releasing peptide (h-GRP). Bombesin and bombesin-like peptides display a number of biological activities (J.H.
- the compounds of the present invention due to the alkylating moiety, display greater receptor affinity than the parent peptides, and behave as receptor antagonists either when given in combination with bombesin or when administered 24 hours before bombesin challenge. In addition, owing to the presence of reduced peptide bonds, water solubility and, in many cases, also antagonistic properties are increased.
- the peptides of the formula I therefore, find application in the therapy of human neoplasms which are modulated in their growth and progression by peptides of the GRP family, either directly or in concert with other growth factors.
- alkylating analogues can be used in the management of the clinical symptoms associates with these deseases and due to hypersecretion of GRP-like peptides.
- the compounds of the invention can be administered by the usual routes, for example, parenterally, e.g. by intravenous injection or infusion, or by intramuscular, subcutaneous, intracavity and intranasal administration.
- the dosage depends on the age, weight and condition of the patient and on the administration route.
- the toxicity of the peptides of the present invention is quite negligible.
- the invention also provides pharmaceutical compositions containing a compound of formula (I) as the active substance, in association with one or more pharmaceutically acceptable excipients.
- compositions of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
- solutions for intravenous injection or infusion may contain as carrier, for example, sterile water or, preferably, they may be in the form of sterile aqueous isotonic saline solutions.
- Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols (e.g., propylene glycol) and, if desired, a suitable amount of lidocaine hydrochloride.
- neuroendocrine neoplasms such as small cell lung carcinoma and prostatic carcinoma
- a method of treating neuroendocrine neoplasms comprising administering to the said patients a composition of the invention.
- B KH 2 PO 4 20 mM, pH 3.5/acetonitrile 3/7 by volume.
- the elution was programmed with a linear gradient from 60% to 90% B over a period of 20 min (System A) or from 30 to 70% B over a period of 15 min (System B), and then isocratically for 15 min, with a flow rate of 1 ml/min.
- peptides were characterized by their retention time (RT).
- reaction mixture was kept for 60 min at -12°C, then for 30 min at 0°C.
- the solvent was removed in vacuo and the residue was dissolved in AcOEt, washed with 5% NaHCO 3 and then brine to neutrality. After drying over Na 2 SO 4 , the solvent was evaporated and the oily residue purified by flash-chromatography on silica gel, eluting with AcOEt containing increasing amount of MeOH (from 0.5% to 10%).
- the product was recovered by evaporation of the solvents and trituration with Et 2 O: 1.23 g (70.7% yield) of compound Im were obtained: m.p. 70°C (mod.) - 90°C (dec); FD-MS: m/z 651 (100, MH + ) ; Rf c 0.57; RT A 12.0.
- Boc-pMel-OSu [prepared extemporaneously from 259 mg (0.64 mmol) of Boc-pMel-OH (see our UK Pat. Appl. No 8906000.9), 77 mg (0.67 mmol) of HOSu and 132 mg (0.64 mmol) of DCC in 5 ml of DMF] were added dropwise to a cooled solution (0°C) of 500 mg (0.43 mmol) of H-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu ⁇ (CH 2 NH) Met-NH 2 ⁇ 2 H HCl (Ip) and 0.096 ml (0.87 mmol) of NMM in 10 ml of DMF.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019910700701A KR920701242A (en) | 1989-11-06 | 1990-11-02 | Reduced irreversible bombesin antagonist |
FI913277A FI913277A0 (en) | 1989-11-06 | 1991-07-05 | REDUCERADE IRONVERSIBLA BOMBESINANTAGONISTER. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8925024.5 | 1989-11-06 | ||
GB898925024A GB8925024D0 (en) | 1989-11-06 | 1989-11-06 | Reduced irreversible bombesin antagonists |
GB909006413A GB9006413D0 (en) | 1990-03-22 | 1990-03-22 | Reduced irreversible bombesin antagonists |
GB9006413.0 | 1990-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991006563A1 true WO1991006563A1 (en) | 1991-05-16 |
Family
ID=26296160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1990/001836 WO1991006563A1 (en) | 1989-11-06 | 1990-11-02 | Reduced irreversible bombesin antagonists |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0452447A1 (en) |
JP (1) | JPH04502629A (en) |
KR (1) | KR920701242A (en) |
AU (1) | AU6610390A (en) |
CA (1) | CA2045494A1 (en) |
HU (1) | HUT58763A (en) |
IE (1) | IE903958A1 (en) |
IL (1) | IL96216A0 (en) |
WO (1) | WO1991006563A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428018A (en) * | 1992-02-07 | 1995-06-27 | Merrell Dow Pharmaceuticals Inc. | Phenylalanine analogs of bombesin |
US5428019A (en) * | 1991-05-23 | 1995-06-27 | Merrell Dow Pharmaceuticals Inc. | Bombesin analogs |
US5834433A (en) * | 1990-07-26 | 1998-11-10 | Merrell Pharmaceuticals Inc. | Compounds and pharmaceutical uses of peptides of bombesin and GRP |
EP2161037A2 (en) | 2003-04-22 | 2010-03-10 | Ipsen Pharma | Camptothecin-Somatostatin conjugates |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011207432A1 (en) * | 2010-01-25 | 2012-08-02 | Cornell University | Aromatic-cationic peptides and uses of same |
IL276300B1 (en) * | 2012-09-25 | 2024-06-01 | Advanced Accelerator Applications Usa Inc | Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0309297A2 (en) * | 1987-09-24 | 1989-03-29 | The Administrators of The Tulane Educational Fund | Therapeutic peptides |
EP0339193A1 (en) * | 1988-04-14 | 1989-11-02 | FARMITALIA CARLO ERBA S.r.l. | Peptide ligands for bombesin receptors |
WO1990001037A1 (en) * | 1988-07-21 | 1990-02-08 | Farmitalia Carlo Erba S.R.L. | Irreversible peptide ligands for bombesin receptors |
WO1990003980A1 (en) * | 1988-10-14 | 1990-04-19 | Administrators Of The Tulane Educational Fund | Therapeutic peptides |
-
1990
- 1990-11-02 HU HU912604A patent/HUT58763A/en unknown
- 1990-11-02 JP JP2514747A patent/JPH04502629A/en active Pending
- 1990-11-02 AU AU66103/90A patent/AU6610390A/en not_active Abandoned
- 1990-11-02 IL IL96216A patent/IL96216A0/en unknown
- 1990-11-02 WO PCT/EP1990/001836 patent/WO1991006563A1/en not_active Application Discontinuation
- 1990-11-02 CA CA002045494A patent/CA2045494A1/en not_active Abandoned
- 1990-11-02 IE IE395890A patent/IE903958A1/en unknown
- 1990-11-02 EP EP90915774A patent/EP0452447A1/en not_active Ceased
- 1990-11-02 KR KR1019910700701A patent/KR920701242A/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0309297A2 (en) * | 1987-09-24 | 1989-03-29 | The Administrators of The Tulane Educational Fund | Therapeutic peptides |
EP0339193A1 (en) * | 1988-04-14 | 1989-11-02 | FARMITALIA CARLO ERBA S.r.l. | Peptide ligands for bombesin receptors |
WO1990001037A1 (en) * | 1988-07-21 | 1990-02-08 | Farmitalia Carlo Erba S.R.L. | Irreversible peptide ligands for bombesin receptors |
WO1990003980A1 (en) * | 1988-10-14 | 1990-04-19 | Administrators Of The Tulane Educational Fund | Therapeutic peptides |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834433A (en) * | 1990-07-26 | 1998-11-10 | Merrell Pharmaceuticals Inc. | Compounds and pharmaceutical uses of peptides of bombesin and GRP |
US5428019A (en) * | 1991-05-23 | 1995-06-27 | Merrell Dow Pharmaceuticals Inc. | Bombesin analogs |
US5428018A (en) * | 1992-02-07 | 1995-06-27 | Merrell Dow Pharmaceuticals Inc. | Phenylalanine analogs of bombesin |
EP2161037A2 (en) | 2003-04-22 | 2010-03-10 | Ipsen Pharma | Camptothecin-Somatostatin conjugates |
EP2662087A1 (en) | 2003-04-22 | 2013-11-13 | Ipsen Pharma | Somatostatin vectors |
Also Published As
Publication number | Publication date |
---|---|
CA2045494A1 (en) | 1991-05-07 |
HU912604D0 (en) | 1992-01-28 |
EP0452447A1 (en) | 1991-10-23 |
AU6610390A (en) | 1991-05-31 |
JPH04502629A (en) | 1992-05-14 |
KR920701242A (en) | 1992-08-11 |
HUT58763A (en) | 1992-03-30 |
IL96216A0 (en) | 1991-08-16 |
IE903958A1 (en) | 1991-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI104252B (en) | Method for solid phase chemical synthesis of therapeutically useful peptides | |
JP2514518B2 (en) | Somatostatin-like amide derivatives of heptapeptide and octapeptide, antitumor agent containing the same | |
US20060281685A1 (en) | Methods of treatment using novel lhrh antagonists having improved solubility properties | |
CA2097192C (en) | Bombesin antagonists | |
EP0215171A2 (en) | Peptides | |
EP0380623B1 (en) | Irreversible peptide ligands for bombesin receptors | |
US5620959A (en) | Bombesin antagonists | |
EP0339193B1 (en) | Peptide ligands for bombesin receptors | |
WO1991006563A1 (en) | Reduced irreversible bombesin antagonists | |
EP0101929B1 (en) | Polypeptide-diesters, their production and use | |
AU630715B2 (en) | Irreversible bombesin antagonists | |
AU8311191A (en) | Bombesin antagonists | |
CA2405724C (en) | Substance p analogs for the treatment of cancer | |
RU2088592C1 (en) | Therapeutic peptides or their pharmaceutically acceptable salts | |
PT95779A (en) | Process for the preparation of peptide derivatives antagonistic to irreversible reduced bombesin | |
JPH08253498A (en) | Bombesin analog | |
CA2144264A1 (en) | Bombesin analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2045494 Country of ref document: CA Ref document number: 1990915774 Country of ref document: EP Ref document number: 913277 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1990915774 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1990915774 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990915774 Country of ref document: EP |